STX Stock Overview
A commercial stage specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Shield Therapeutics plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£0.045 |
52 Week High | UK£0.13 |
52 Week Low | UK£0.011 |
Beta | 1.42 |
11 Month Change | 47.54% |
3 Month Change | 109.30% |
1 Year Change | -59.55% |
33 Year Change | -89.16% |
5 Year Change | -97.55% |
Change since IPO | -97.13% |
Recent News & Updates
Recent updates
Shield Therapeutics plc's (LON:STX) Shares Leap 44% Yet They're Still Not Telling The Full Story
Aug 01Increases to Shield Therapeutics plc's (LON:STX) CEO Compensation Might Cool off for now
Jun 13Market Might Still Lack Some Conviction On Shield Therapeutics plc (LON:STX) Even After 35% Share Price Boost
May 22Here's Why We're Watching Shield Therapeutics' (LON:STX) Cash Burn Situation
Mar 02What Does The Future Hold For Shield Therapeutics plc (LON:STX)? These Analysts Have Been Cutting Their Estimates
May 06Shield Therapeutics (LON:STX) Shareholders Have Enjoyed An Impressive 111% Share Price Gain
Mar 15We're Interested To See How Shield Therapeutics (LON:STX) Uses Its Cash Hoard To Grow
Jan 27Trade Alert: The CEO & Director Of Shield Therapeutics plc (LON:STX), Timothy Watts, Has Just Spent UK£70k Buying 22% More Shares
Dec 15Shareholder Returns
STX | GB Pharmaceuticals | GB Market | |
---|---|---|---|
7D | 2.3% | -0.7% | -0.9% |
1Y | -59.6% | 21.6% | 9.5% |
Return vs Industry: STX underperformed the UK Pharmaceuticals industry which returned 21.6% over the past year.
Return vs Market: STX underperformed the UK Market which returned 9.5% over the past year.
Price Volatility
STX volatility | |
---|---|
STX Average Weekly Movement | 18.5% |
Pharmaceuticals Industry Average Movement | 6.5% |
Market Average Movement | 4.6% |
10% most volatile stocks in GB Market | 9.2% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: STX's share price has been volatile over the past 3 months.
Volatility Over Time: STX's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 73 | Anders Lundstrom | www.shieldtherapeutics.com |
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.
Shield Therapeutics plc Fundamentals Summary
STX fundamental statistics | |
---|---|
Market cap | UK£35.19m |
Earnings (TTM) | -UK£25.29m |
Revenue (TTM) | UK£9.94m |
3.5x
P/S Ratio-1.4x
P/E RatioIs STX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
STX income statement (TTM) | |
---|---|
Revenue | US$13.09m |
Cost of Revenue | US$9.06m |
Gross Profit | US$4.03m |
Other Expenses | US$37.32m |
Earnings | -US$33.29m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.043 |
Gross Margin | 30.78% |
Net Profit Margin | -254.44% |
Debt/Equity Ratio | 131.9% |
How did STX perform over the long term?
See historical performance and comparison